Table 2.
Serum FABP3 and FABP4 concentrations in psoriatic patients before treatment by PASI score in three groups (<10, 10–20, >20) compared to the controls
| Controls | Psoriatic patients | |||
|---|---|---|---|---|
| <10 | 10–20 | >20 | ||
| n = 7 | n = 16 | n = 14 | ||
| FABP3 (ng/ml) | 7.8 (0.6–28) | 11.5 (4.2–31.8) | 19.1 (7.5–31.1) | 6.8 (2.1–30.0) |
| p value (vs. controls) | 0.77 | 0.19 | 0.96 | |
| FABP4 (pg/ml) | 21,445 (17,449–24,725) | 32,257 (27,389–39,328) | 26,518 (19,332–32,205) | 23,085 (19,024–31,091) |
| p value (vs. controls) | 0.002* | 0.14 | 0.35 | |
Statistical analysis using the Mann–Whitney U test, median (25–75% CI)
* Statistically significant (p < 0.05)